Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. more
Time Frame | CLRB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -18.27% | 0.49% | -1.93% |
1-Month Return | -77.95% | -3.1% | -3.69% |
3-Month Return | -86.56% | -8.59% | 0.82% |
6-Month Return | -87.99% | -4.57% | 3.51% |
1-Year Return | -91.86% | -0.94% | 21.91% |
3-Year Return | -95.97% | 2.88% | 24.73% |
5-Year Return | -98.95% | 35.84% | 78.4% |
10-Year Return | -99.99% | 98.8% | 187.28% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
Cost of Revenue | 207.93K | 227.64K | 238.87K | 192.38K | 192.38K | [{"date":"2020-12-31","value":87.05,"profit":true},{"date":"2021-12-31","value":95.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.54,"profit":true},{"date":"2024-12-31","value":80.54,"profit":true}] |
Gross Profit | (207.93K) | (227.64K) | (238.87K) | (192.38K) | (192.38K) | [{"date":"2020-12-31","value":-20792900,"profit":false},{"date":"2021-12-31","value":-22763600,"profit":false},{"date":"2022-12-31","value":-23886700,"profit":false},{"date":"2023-12-31","value":-19237500,"profit":false},{"date":"2024-12-31","value":-19237500,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
Operating Expenses | 15.29M | 24.13M | 28.81M | 38.96M | 38.96M | [{"date":"2020-12-31","value":39.25,"profit":true},{"date":"2021-12-31","value":61.94,"profit":true},{"date":"2022-12-31","value":73.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
Operating Income | (15.29M) | (24.13M) | (28.81M) | (38.96M) | (38.96M) | [{"date":"2020-12-31","value":-1529034900,"profit":false},{"date":"2021-12-31","value":-2413128000,"profit":false},{"date":"2022-12-31","value":-2881377300,"profit":false},{"date":"2023-12-31","value":-3896064300,"profit":false},{"date":"2024-12-31","value":-3896064300,"profit":false}] |
Total Non-Operating Income/Expense | 207.07K | 11.20K | 305.04K | 1.31M | - | [{"date":"2020-12-31","value":15.78,"profit":true},{"date":"2021-12-31","value":0.85,"profit":true},{"date":"2022-12-31","value":23.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
Pre-Tax Income | (15.09M) | (24.12M) | (28.66M) | (38.04M) | (38.04M) | [{"date":"2020-12-31","value":-1509417200,"profit":false},{"date":"2021-12-31","value":-2412236200,"profit":false},{"date":"2022-12-31","value":-2866125400,"profit":false},{"date":"2023-12-31","value":-3804349600,"profit":false},{"date":"2024-12-31","value":-3804349600,"profit":false}] |
Income Taxes | (337.63K) | (152.20K) | (60.00K) | 60.00K | (60.00K) | [{"date":"2020-12-31","value":-562.72,"profit":false},{"date":"2021-12-31","value":-253.66,"profit":false},{"date":"2022-12-31","value":-100,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-100,"profit":false}] |
Income After Taxes | (14.76M) | (23.97M) | (28.60M) | (38.10M) | - | [{"date":"2020-12-31","value":-1475654200,"profit":false},{"date":"2021-12-31","value":-2397016300,"profit":false},{"date":"2022-12-31","value":-2860125400,"profit":false},{"date":"2023-12-31","value":-3810349600,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (15.09M) | (24.12M) | (28.60M) | (37.75M) | - | [{"date":"2020-12-31","value":-1509417200,"profit":false},{"date":"2021-12-31","value":-2412236200,"profit":false},{"date":"2022-12-31","value":-2860125400,"profit":false},{"date":"2023-12-31","value":-3774993100,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
Net Income | (14.76M) | (23.97M) | (28.60M) | (37.98M) | (37.98M) | [{"date":"2020-12-31","value":-1475654200,"profit":false},{"date":"2021-12-31","value":-2397016300,"profit":false},{"date":"2022-12-31","value":-2860125400,"profit":false},{"date":"2023-12-31","value":-3798349600,"profit":false},{"date":"2024-12-31","value":-3798349600,"profit":false}] |
EPS (Diluted) | (9.00) | (4.30) | (4.05) | (2.93) | (1.14) | [{"date":"2020-12-31","value":-900,"profit":false},{"date":"2021-12-31","value":-430,"profit":false},{"date":"2022-12-31","value":-405,"profit":false},{"date":"2023-12-31","value":-293,"profit":false},{"date":"2024-12-31","value":-114,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CLRB | |
---|---|
Cash Ratio | 1.69 |
Current Ratio | 1.77 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CLRB | |
---|---|
ROA (LTM) | -166.00% |
ROE (LTM) | -796.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CLRB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.59 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.41 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CLRB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 7.52 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
Cellectar Biosciences Inc (CLRB) share price today is $0.284
Yes, Indians can buy shares of Cellectar Biosciences Inc (CLRB) on Vested. To buy Cellectar Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CLRB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cellectar Biosciences Inc (CLRB) via the Vested app. You can start investing in Cellectar Biosciences Inc (CLRB) with a minimum investment of $1.
You can invest in shares of Cellectar Biosciences Inc (CLRB) via Vested in three simple steps:
The 52-week high price of Cellectar Biosciences Inc (CLRB) is $4.45. The 52-week low price of Cellectar Biosciences Inc (CLRB) is $0.22.
The price-to-earnings (P/E) ratio of Cellectar Biosciences Inc (CLRB) is
The price-to-book (P/B) ratio of Cellectar Biosciences Inc (CLRB) is 7.52
The dividend yield of Cellectar Biosciences Inc (CLRB) is 0.00%
The market capitalization of Cellectar Biosciences Inc (CLRB) is $12.13M
The stock symbol (or ticker) of Cellectar Biosciences Inc is CLRB